News | Radiation Therapy | September 19, 2017

Highlights include Halcyon IMRT platform and HyperArc high-definition radiotherapy system

Varian to Showcase Latest Radiation Therapy Technologies and Software at ASTRO 2017

September 19, 2017 — Varian Medical Systems announced it will be demonstrating its new Halcyon platform and HyperArc high-definition radiotherapy (HDRT) at the 2017 American Society for Radiation Oncology (ASTRO) Annual Meeting, Sept. 24-27 in San Diego. The company also will host its Users Meeting on Sept. 23 prior to the ASTRO meeting.

The Halcyon platform helps simplify and enhance virtually every aspect of image-guided volumetric intensity modulated radiotherapy (IMRT), while HyperArc HDRT is an advanced type of radiosurgery treatment.

In addition to Halcyon and HyperArc, Varian will showcase these solutions for simplifying and increasing access to advanced cancer care:

  • Eclipse 15.5 featuring treatment planning for HyperArc HDRT, RapidPlan knowledge-based planning, multicriteria optimization (MCO), plus fast optimization and dose calculation;
  • Iterative cone beam computed tomography (CBCT) on the TrueBeam platform, which produces exceptionally high quality images, according to the company, for better visualization of soft tissue structures;
  • ProBeam proton therapy, configurable as single- or multi-room solutions featuring gantries that rotate a full 360 degrees, RapidScan high-speed pencil-beam scanning for single-breath-hold lung SBPT and iterative CBCT for enhanced soft tissue resolution; and
  • Varian Marketplace, a digital marketplace for Varian and customer apps and software product extensions to solve real-world clinical and operational problems.

The Varian Users Meeting will provide attendees with new insights on the latest Varian technology. Topics include:

  • Early experience with the Halcyon system;
  • Multicriteria optimization and high-performance computing;
  • Using 360 Oncology care management to make multidisciplinary tumor boards smarter and more efficient;
  • Robust planning for proton therapy using the Eclipse system;
  • Multi-modality imaging in treatment planning, delivery and response assessment; and
  • First clinical impressions of HyperArc for treating brain metastases.

For more information: www.varian.com


Related Content

News | Artificial Intelligence

March 28, 2024 — As artificial intelligence (AI) makes its way into cancer care – and into discussions between ...

Time March 28, 2024
arrow
News | Prostate Cancer

March 27, 2024 — A minimally invasive treatment using MRI and transurethral ultrasound instead of surgery or radiation ...

Time March 27, 2024
arrow
Videos | Radiation Oncology

In the conclusion of this 3-part video series on recent advancements in diagnostic radiology, current editorial advisory ...

Time March 19, 2024
arrow
News | Breast Imaging

March 18, 2024 — QT Imaging Holdings, Inc., a medical device company engaged in research, development, and ...

Time March 18, 2024
arrow
Feature | Radiation Oncology | By Christine Book

Appreciating the considerable advances in the clinical application of artificial intelligence (AI) within healthcare ...

Time March 06, 2024
arrow
News | FDA

March 1, 2024 — Varian, a Siemens Healthineers company, announced that it has received 510(k) clearance from the U.S ...

Time March 01, 2024
arrow
News | Breast Imaging

February 22, 2024 — The FAST-Forward randomized trial from the UK found that ultrahypofractionated whole breast ...

Time February 22, 2024
arrow
News | Radiation Oncology

February 22, 2024 — The National Institutes of Health has launched a clinical trials network to evaluate emerging ...

Time February 22, 2024
arrow
News | Radiation Oncology

February 14, 2024 — Accuray Incorporated announced that the team at Quebec’s Montérégie Integrated Cancer Center, part ...

Time February 14, 2024
arrow
News | Radiation Oncology

February 12, 2024 — Radformation, a global pioneer in radiation oncology software solutions, is pleased to announce its ...

Time February 12, 2024
arrow
Subscribe Now